Daptomycin Use in Children: Experience with Various Types of Infection and Age Groups
dc.creator | Syrogiannopoulos G.A., Michoula A.N., Petinaki E., Grivea I.N. | en |
dc.date.accessioned | 2023-01-31T10:05:20Z | |
dc.date.available | 2023-01-31T10:05:20Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1097/INF.0000000000001629 | |
dc.identifier.issn | 08913668 | |
dc.identifier.uri | http://hdl.handle.net/11615/79557 | |
dc.description.abstract | Background: In Greece, there are high rates of methicillin (40%-60%) and clindamycin (15%-25%) resistance among community-acquired Staphylococcus aureus isolates. Therefore, we sought to identify other antimicrobial treatment options such as daptomycin. Methods: We studied retrospectively all pediatric infections treated with daptomycin at the University General Hospital of Larissa, Greece, from January 1, 2007, to June 16, 2016. Results: Of a total of 128 patients (median age: 2.8 years; range: 8 days to 14.5 years; 76.6% <7 years) treated with daptomycin, 45 (35.2%) had invasive infection, most frequently musculoskeletal, and 83 (64.8%) had noninvasive infection, that is, complicated skin and soft tissue infection. S. aureus was the most commonly recovered pathogen (n = 61) (63.9% methicillin-resistant isolates, 21.3% clindamycin-resistant). The average daily dose of daptomycin was 10 mg/kg qd, and the median duration of therapy was 10 days. Daptomycin was administered alone (n = 61) or in combination therapy (n = 67), most frequently with rifampin (n = 40) and/or a β-lactam antibiotic (n = 33). Open or closed drainage was performed in 86 (67.2%) of the total number of patients. Of 128 treated patients, 123 (96.1%) achieved clinical success, 114 (89.1%) had complete remission, and 9 (7%) had improvement of their disease. There were no failures with daptomycin therapy. The adverse events were of no clinical significance. Conclusions: Daptomycin administered alone or in combination with other antimicrobial agents to children was efficacious and well tolerated in the treatment of complicated infections of suspected or proven staphylococcal etiology. © 2017 Wolters Kluwer Health, Inc. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Pediatric Infectious Disease Journal | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030615162&doi=10.1097%2fINF.0000000000001629&partnerID=40&md5=796ab2a1c9483d9c196e9e6efc2e5158 | |
dc.subject | aminopenicillin | en |
dc.subject | ampicillin | en |
dc.subject | aztreonam | en |
dc.subject | beta lactam | en |
dc.subject | cefotaxime | en |
dc.subject | cephalosporin | en |
dc.subject | clindamycin | en |
dc.subject | daptomycin | en |
dc.subject | meropenem | en |
dc.subject | quinolone derivative | en |
dc.subject | rifampicin | en |
dc.subject | antiinfective agent | en |
dc.subject | daptomycin | en |
dc.subject | abscess | en |
dc.subject | adolescent | en |
dc.subject | antibiotic therapy | en |
dc.subject | arthritis | en |
dc.subject | Article | en |
dc.subject | child | en |
dc.subject | clinical outcome | en |
dc.subject | closed drainage | en |
dc.subject | combination drug therapy | en |
dc.subject | community acquired infection | en |
dc.subject | drug tolerability | en |
dc.subject | female | en |
dc.subject | Greece | en |
dc.subject | groups by age | en |
dc.subject | hospital infection | en |
dc.subject | human | en |
dc.subject | infant | en |
dc.subject | infection | en |
dc.subject | lymphadenitis | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | medical record review | en |
dc.subject | methicillin resistant Staphylococcus aureus | en |
dc.subject | monotherapy | en |
dc.subject | musculoskeletal infection | en |
dc.subject | newborn | en |
dc.subject | nonhuman | en |
dc.subject | orbit cellulitis | en |
dc.subject | osteomyelitis | en |
dc.subject | patient safety | en |
dc.subject | preschool child | en |
dc.subject | priority journal | en |
dc.subject | pyomyositis | en |
dc.subject | remission | en |
dc.subject | retrospective study | en |
dc.subject | skin infection | en |
dc.subject | soft tissue infection | en |
dc.subject | Staphylococcus infection | en |
dc.subject | treatment duration | en |
dc.subject | Bacterial Infections | en |
dc.subject | microbiology | en |
dc.subject | Muscular Diseases | en |
dc.subject | Soft Tissue Infections | en |
dc.subject | treatment outcome | en |
dc.subject | Adolescent | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Bacterial Infections | en |
dc.subject | Child | en |
dc.subject | Child, Preschool | en |
dc.subject | Daptomycin | en |
dc.subject | Female | en |
dc.subject | Greece | en |
dc.subject | Humans | en |
dc.subject | Infant | en |
dc.subject | Infant, Newborn | en |
dc.subject | Male | en |
dc.subject | Muscular Diseases | en |
dc.subject | Retrospective Studies | en |
dc.subject | Soft Tissue Infections | en |
dc.subject | Treatment Outcome | en |
dc.subject | Lippincott Williams and Wilkins | en |
dc.title | Daptomycin Use in Children: Experience with Various Types of Infection and Age Groups | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |